Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Tuesday broker round-up UPDATE

Tue, 29th Oct 2013 08:48

Adept Telecom: Northland Capital revises target price from 145p to 165p and reiterates a buy recommendation.Aggreko: JP Morgan reduces target price from 1620p to 1505p, while its neutral recommendation remains unchanged. UBS cuts target price from 1610p to 1555p keeping its neutral rating.APR Energy: Investec raises target price from 900p to 1150p and stays with its hold recommendation.ARM Holdings: RBC Capital moves target price from 1050p to 1080p and retains an outperform rating.Barratt Developments: Liberum Capital ups target price from 374p to 387p and maintains a buy recommendation.Bellway: Liberum Capital takes target price from 1700p to 1760p and retains its buy recommendation.Berkeley Group: Liberum Capital raises target price from 2400p to 2634p, while reiterating a hold recommendation.Blur Group: Liberum Capital raises target price from 400p to 700p and stays with its buy recommendation.Bovis Homes Group: Liberum Capital increases target price from 791p to 911p upgrading to buy.Braemer Shipping Services: Westhouse Securities takes target price from 515p to 590p and reiterates an add rating.BT Group: Bank of America ups target price from 350p to 400p retaining a buy recommendation.Coca-Cola HBC: Nomura reduces target price from 1600p to 1500p and downgrades from neutral to reduce.EMIS Group: N+1 Singer takes target price to 748p upgrading from hold to buy.Europa Oil & Gas: Northland Capital shifts target price from 17.60p to 19.70p and stays with its buy recommendation.Genel Energy: RBC Capital revises target price from 1100p to 1300p and maintains an outperform rating.Getech: WH Ireland shifts target price from 86p to 92p staying with its buy recommendation.GlaxoSmithKline: Barclays lowers target price from 1555p to 1545p and retains an equal-weight rating.Halfords Group: Investec ups target price from 400p to 460p and maintains its buy recommendation.HSBC Holdings: Goldman Sachs cuts target price from 950p to 900p, while reiterating its strong buy recommendation.ITV: Berenberg raises target price from 91p to 155p, but downgrades from hold to sell.Kirkland Lake Gold: Investec cuts target price from 377p to 353p, while its buy recommendation is kept.Lloyds Banking Group: Goldman Sachs shifts target price from 75p to 76p and maintains a neutral rating. Numis downgrades to hold with a target price of 85p.Microgen: Investec lowers target price from 147p to 143p and keeps a hold recommendation. Westhouse Securities cuts target price from 155p to 145p, while upgrading to add.Next Fifteen Communications: Canaccord Genuity reduces target price from 120p to 94p downgrading from buy to hold.Persimmon: Liberum Capital takes target price from 1245p to 1261p, while its hold recommendation remains unaltered.Playtech: Investec places its target price (prev.: 630p) under review, while staying with its hold recommendation. Canaccord Genuity raises target price from 780p to 825p retaining its buy recommendation. Daniel Stewart increases target price from 790p to 840p and keeps its buy recommendation.Redrow: Liberum Capital ups target price from 241p to 304p and upgrades to buy.Regus: Investec downgrades from buy to add with a target price of 205p.Salamander Energy: RBC Capital cuts target price from 250p to 170p downgrading to neutral.Shire: Barclays increases target price from 2515p to 2800p, while its overweight rating is kept.Stagecoach: Investec places its target price (prev.: 325p) under review, while leaving its add rating unchanged.Standard Chartered: Goldman Sachs reduces target price from 1900p to 1700p leaving its neutral rating unaltered.Taylor Wimpey: Liberum Capital moves target price from 113p to 127p and keeps a buy recommendation.
More News
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.